By Bill Moran and Rich Ptak
Now, Linux is the fastest growing OS in the broader market,
and IBM plans to capture a portion of that growth for the mainframe. LinuxONE
is their strategy to do so.
What’s the connection between IBM’s new LinuxONE offering
and the search for a cure for the deadly disease, ALS[1]? You
might say “Nothing” or “Not much,” but that’s wrong. Read on to discover how IBM’s
LinuxONE platform plays an important role in the search. But, before discussing
IBM’s contribution, let’s review the LinuxONE offering
.
IBM believes combining the best of Linux with the best of
the enterprise computing can be a real winner. They expect the new LinuxONE
offerings will appeal to customers already familiar with Linux but who know
little about the mainframe. This reasoning appears correct to us with the
potential of a very successful system.
We won’t cover all of the details about IBM’s LinuxONE.
These are available in the references provided below[2].
Instead, we focus on what we consider the most significant and important
features. We also want to explore some humorous side effects of the offering
and some problems that IBM may have along the way.
What’s new in the strategy? What
difference does it make? First. We’ll look at the new items; then we’ll cover
what it all means. The new items by categories are:
1. Expanded
relations with Linux Community
2. Brand
New Cloud offerings
3. Hardware
Systems
4. Software
5. Pricing
models
These mark a major change in mainframe direction as well as
an expansion outside the traditional customer base.
No comments:
Post a Comment